Critical data for the COVID-19 vaccine announced by Russia last month were published Friday in a major medical journal for scientific review, a key step in the approval process.
Sept.4 (UPI) — Critical data for the COVID-19 vaccine announced by Russia last month were published Friday in a major medical journal for scientific review, a key step in the approval process. British medical journal The Lancet published the early-stage data that shows the Sputnik V vaccine didn’t produce serious adverse effects among 76 adults participating in a pair of 42-day trials. The vaccine elicited an antibody response in all participants, it added, as well as responses in T cells and neutralizing antibodies with in 28 days. “Large, long-term trials including a placebo comparison and further monitoring, are needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection,” the authors at the Gamaleya National Center of Epidemiology and Microbiology in Moscow state in the study.
